Instrument Inactif

Communiqués Baxalta Inc

Actions

US07177M1036

Produits pharmaceutiques

Cours en clôture NYSE
- ^USD	-

12/01/16	Wall Street termine dans le désordre une séance volatile	RE
11/01/16	Alcoa : Wall Street termine dans le désordre une séance volatile	RE

Communiqués

03/06/16	Baxalta : Shire Completes Combination With Baxalta Creating the Global Leader in Rare Diseases and Highly Specialized Conditions	PR
27/05/16	Baxalta : CORRECTING and REPLACING Baxalta Shareholders Vote to Approve Combination	BU
26/05/16	Baxalta : OncoResponse Secures Investment from Baxalta	BU
25/05/16	Baxalta : Reports Positive Phase 1 Results for BAX 930, Investigational Recombinant ADAMTS13 to Treat Hereditary Thrombotic Thrombocytopenic Purpura (hTTP)	BU
25/05/16	Baxalta : Thunderbolt Pharma, Inc., a Vitesse Biologics Company, Acquires Rights to BAFF/APRIL Dual Antagonist Program from Astellas Pharma Inc.	BU
23/05/16	Baxalta : Announces Preliminary Merger Consideration Election Results	BU
19/05/16	Baxalta : Merrimack and Baxalta Announce Initiation of Phase 1 Study of MM-151 in Combination with the ONIVYDE® (irinotecan liposome injection) Regimen in Metastatic Colorectal Cancer	PR
10/05/16	Baxalta : Declares Quarterly Dividend	BU
04/05/16	Baxalta : Baxter Increases the Size of Its Previously Announced Offer to Exchange Shares of Baxter for Shares of Baxalta	BU
02/05/16	Baxalta : Receives Positive Opinion from Europe’s CHMP for HYQVIA to Treat Pediatric Patients	BU
28/04/16	Baxalta : Exceeds Guidance and Delivers Strong Sales and Earnings for First Quarter 2016	BU
21/04/16	Baxalta : Baxter Initiates Offer to Exchange Shares of Baxter for Shares of Baxalta	BU
21/04/16	Baxalta : Supports Research to Raise Awareness of Treatment Burden on Patients during the Sixth Annual World Primary Immunodeficiency Week	BU
14/04/16	Baxalta : Announces Date for Special Meeting of Stockholders to Vote on Combination With Shire	BU
04/04/16	Baxalta : Expands Global Reach of ADYNOVATE for Hemophilia A Patients with Approval in Japan	BU
16/03/16	Baxalta : Announces Pricing of Secondary Offering of Common Stock	BU
15/03/16	Baxalta : Announces Secondary Offering of Common Stock	BU
04/03/16	Baxalta : Commences Phase 1 Clinical Trial of BAX 826, the Company’s Second Extended Half-Life Factor VIII Treatment for Hemophilia A	BU
03/03/16	Baxalta : to Showcase Innovation Leadership in Primary Immune Deficiencies During 2016 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting	BU
02/03/16	Baxalta : Submits Marketing Authorization Application to the European Medicines Agency for ADYNOVI for Treatment of Hemophilia A Patients	BU
26/02/16	Baxalta : Announces Submission of Supplemental BLAs to Expand Use of ADYNOVATE to Pediatric Patients and Surgical Settings	PR
25/02/16	Baxalta : Announces Submission of Supplemental BLAs to Expand Use of ADYNOVATE to Pediatric Patients and Surgical Settings	BU
25/02/16	Baxalta : and Precision BioSciences form Global Genome Editing Collaboration in Immuno-Oncology	BU
23/02/16	Baxalta : Declares Quarterly Dividend	BU
16/02/16	Baxalta : Posts Strong Fourth Quarter 2015 Sales and Earnings; Positive Momentum Continues with Achievement of Key Milestones	BU